In comparison with the NC-OE+anti-PD1 group, anti-PD1 therapy failed to achieve a significant anti-tumor effect in the FSTL3-OE+anti-PD1 group, as shown in Fig. 8A. This evidence concerns the gene FSTL3 and neoplasm.